VivoSeq
Oncology

B-Cell Lymphoid Malignancies

0

Pipeline Programs↗

1

Active Trials↗

4

Companies Involved↗

B-cell Lymphoid Malignancies is an early-stage landscape with 0 programs across 4 companies. The most active players are Shanghai Escugen Biotechnology Co., Ltd, BeiGene, TG Therapeutics, Inc..

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

57/100

Attrition Rate

38/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Shanghai Escugen Biotechnology Co., Ltd

0 programs

PreclinicalBeiGene logo

BeiGene

0 programs

PreclinicalT

TG Therapeutics, Inc.

0 programs

PreclinicalO

Oncternal Therapeutics, Inc

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

8

clinical trials

Completed4 · 50%
Withdrawn2 · 25%
Terminated1 · 13%
Active, not recruiting1 · 13%

Clinical Trials

Trial Activity

8 trials

Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies
Active, not recruiting·MMedical College of Wisconsin·Phase 1·NCT05270057·11 enrolled
A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies
Completed·SShanghai Escugen Biotechnology Co., Ltd·Phase 1·NCT05822843·13 enrolled
BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies
Completed·BeiGene logoBeiGene·Phase 1·NCT02569476·119 enrolled
A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies
Completed·OOncternal Therapeutics, Inc·Phase 1/2·NCT03088878·95 enrolled
Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies
Completed·BeiGene logoBeiGene·Phase 1/2·NCT02343120·385 enrolled
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
Terminated·TTG Therapeutics, Inc.·Phase 1·NCT01744912·10 enrolled
A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies
Withdrawn·SShanghai Escugen Biotechnology Co., Ltd·Phase 1·NCT05263739
Transplantation of Hematopoietic Stem Cells From HLA-compatible Donors in Patients With B-Cell Lymphoid Malignancies
Withdrawn·BBaptist Health South Florida·Phase 2·NCT04684979

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)